Patents by Inventor Jackie Butler
Jackie Butler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150164893Abstract: The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: February 23, 2015Publication date: June 18, 2015Inventors: Jackie Butler, John Devane, Paul Stark
-
Patent number: 8987322Abstract: The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: GrantFiled: October 19, 2004Date of Patent: March 24, 2015Assignee: Circ Pharma Research and Development LimitedInventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20120070472Abstract: Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject: a) a delay in release of therapeutic levels of the at least one drug for about 2 to about 8 hours; b) a Tmax at about 8 to about 12 hours; c) a drug plasma level within 50% of the peak for greater than or equal to 12 hours; and d) a peak-to-trough ratio of drug plasma levels greater than or equal to about 4.Type: ApplicationFiled: October 11, 2011Publication date: March 22, 2012Applicant: Circ Pharma Research & Development LimitedInventors: John Devane, Jackie Butler
-
Patent number: 7928092Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: June 10, 2010Date of Patent: April 19, 2011Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20100278917Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: ApplicationFiled: June 10, 2010Publication date: November 4, 2010Inventors: John Devane, Jackie Butler
-
Patent number: 7825106Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: March 10, 2006Date of Patent: November 2, 2010Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Patent number: 7737133Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: September 1, 2004Date of Patent: June 15, 2010Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20090246233Abstract: The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia.Type: ApplicationFiled: June 8, 2009Publication date: October 1, 2009Inventors: John Devane, Jackie Butler
-
Publication number: 20060223787Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: ApplicationFiled: March 10, 2006Publication date: October 5, 2006Inventors: John Devane, Jackie Butler
-
Publication number: 20060003001Abstract: Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject: a) a delay in release of therapeutic levels of the at least one drug for about 2 to about 8 hours; b) a Tmax at about 8 to about 12 hours; c) a drug plasma level within 50% of the peak for greater than or equal to 12 hours; and d) a peak-to-trough ratio of drug plasma levels greater than or equal to about 4.Type: ApplicationFiled: February 10, 2005Publication date: January 5, 2006Inventors: John Devane, Jackie Butler
-
Publication number: 20050277691Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: August 17, 2005Publication date: December 15, 2005Applicant: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Patent number: 6967218Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: GrantFiled: January 10, 2003Date of Patent: November 22, 2005Assignee: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20050232992Abstract: Pharmaceutical formulation comprising at least one proton pump inhibitor structured and arranged to provide an initial pH independent time-based delayed-release, and a subsequent extended-release of the at least one proton pump inhibitor.Type: ApplicationFiled: September 2, 2004Publication date: October 20, 2005Applicant: AGI Therapeutics LimitedInventors: John Devane, Jackie Butler, Paul Stark
-
Publication number: 20050119331Abstract: The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: October 19, 2004Publication date: June 2, 2005Inventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20050090473Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: ApplicationFiled: September 1, 2004Publication date: April 28, 2005Inventors: John Devane, Jackie Butler
-
Publication number: 20050090554Abstract: The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia.Type: ApplicationFiled: September 8, 2004Publication date: April 28, 2005Inventors: John Devane, Jackie Butler
-
Publication number: 20040132802Abstract: The present invention is directed to compositions and methods of their use in treating, preventing, and/or managing one or more cardiovascular diseases using at least one poorly water-soluble statin, such as, for example, simvastatin and/or lovastatin. One method of the invention involves delaying release of the poorly water-soluble statin for a time sufficient to avoid metabolism of the statin at or near the gastrointestinal tract wall by the cytochrome P450 3A metabolic system, and releasing said statin in the ileum, colon, or both, with subsequent uptake into the hepatic portal vein and distribution to hepatocytes, wherein HMG-CoA reductase activity may be inhibited with minimal adverse drug interactions.Type: ApplicationFiled: September 3, 2003Publication date: July 8, 2004Inventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20040132806Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof. The present formulations are designed to prevent inactivation of pravastatin in the stomach, limit systemic exposure of the body to pravastatin, and maximize hepatic-specific absorption of the drug. The formulations of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: September 3, 2003Publication date: July 8, 2004Inventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20040029959Abstract: The present invention relates to delayed onset, extended release formulations of isosorbide mononitrates (ISMNs), and methods of their use in treating, preventing, reducing, reversing, and/or managing nitrate tolerance and/or cardiovascular conditions. In particular, the present invention is directed to once-daily delayed onset, extended release formulations that (1) provide a subject with a therapeutically effective amount of ISMNs during the early morning hours prior to and after awakening, (2) continue to provide therapeutically effective amounts of ISMN throughout the waking hours of the day, and (3) provide a reduction, or washout, of ISMN plasma levels to treat, prevent, reduce, reverse, and/or manage nitrate tolerance.Type: ApplicationFiled: August 8, 2002Publication date: February 12, 2004Inventors: John Devane, Paul Stark, John Kelly, Jackie Butler
-
Publication number: 20030176502Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: January 10, 2003Publication date: September 18, 2003Inventors: Jackie Butler, John Devane, Paul Stark